Seattle genetics and merck announce two strategic oncology collaborations

Seattle genetics and merck announce two strategic oncology collaborations.seattle genetics inc - merck to acquire $1 billion equity stake in seattle genetics common stock.seattle genetics inc - companies to co-develop and co-commercialize seattle genetics' antibody-drug conjugate ladiratuzumab vedotin globally.seattle genetics inc - under terms of agreement, seattle genetics will receive a $600 million upfront payment.seattle genetics inc - separately has granted merck an exclusive license to commercialize tukysa(®) (tucatinib).seattle genetics inc - seattle genetics is eligible for progress-dependent milestone payments of up to $2.6 billion for ladiratuzumab vedotin.seattle genetics - granted merck license to commercialize tukysa in asia, middle east & latin america & other regions outside of u.s., canada & europe.seattle genetics inc - merck will make a $1.0 billion equity investment in 5.0 million shares of seattle genetics common stock at a price of $200 per share.seattle genetics inc - will receive $125 million from merck as upfront payment and eligible for progress-dependent milestones of up to $65 million for tukysa.seattle genetics inc - financial impact of these collaborations is not included in seattle genetics' 2020 guidance.seattle genetics inc - would receive tiered royalties on sales of tukysa in merck's territory.seattle genetics - under ladiratuzumab vedotin collaboration, co is eligible to receive up to $4.2 billion.
SGEN Ratings Summary
SGEN Quant Ranking